Jean‐Philippe Pignol

Dalhousie University, Sultan Qaboos University Hospital

Papers

4

Total Citations

31

H-Index

3

About

Jean-Philippe Pignol is a leading radiation oncologist whose research focuses on minimizing the long-term toxicity of breast cancer radiotherapy while preserving its life-saving benefits. His key contributions center on quantifying and reducing the risk of radiation-induced secondary lung cancers, particularly in early-stage breast cancer patients. His most cited work (16 citations) demonstrated that secondary lung cancer risks can offset the benefits of adjuvant radiotherapy after 25–30 years, and that modern techniques can significantly reduce this danger. He has pioneered the use of hyaluronic acid spacers to protect skin during accelerated partial breast irradiation (APBI), and his 2018 randomized trial protocol addresses a critical toxicity concern. More recently, Pignol has developed an artificial intelligence-based clinical decision tool to optimize treatment selection between stereotactic radiation therapy and protons for uveal melanoma, predicting dosimetric outcomes from simple inputs. His work bridges clinical physics and patient safety, directly informing treatment planning to spare healthy tissue. With citations spanning from 2 to 16 per paper, his research has shaped international guidelines on breast radiotherapy technique selection and risk-benefit analysis.

Research Focus

Key Achievements

3
H-Index
4
Papers
31
Total Citations
8
Avg Citations/Paper
🏆 Most Cited Paper
Estimation of Annual Secondary Lung Cancer Deaths Using Various Adjuvant Breast Radiotherapy Techniques for Early-Stage Cancers
16 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 29
🏛 Institutions: Dalhousie University, Sultan Qaboos University Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago